Amgen Fears 'Staggering Loss' After FDA Exclusivity Denial
Amgen Inc. urged the D.C. Circuit on Friday to quickly block generic versions of its lucrative calcium-control drug Sensipar, saying it faces a "staggering loss" of sales because the U.S. Food and...To view the full article, register now.
Already a subscriber? Click here to view full article